Asarina Pharma AB (publ) Year-end Report 2021 released

Report this content

Peter Nordkild, CEO: “We enter the new financial year with renewed energy and optimism after Region Hovedstaden finally signed the required papers for our clinical test sites in Copenhagen, and we achieved ‘First Patient First Visit’ on 16 February in our phase IIa clinical study in Tourette syndrome. We are now moving ahead confidently in our search to develop a safer, entirely novel modality of treatment for Tourette syndrome, and, potentially, OCD.”


  • Total operating expenses in Q4/21 reduced to 8.7 MSEK (24.9 MSEK in Q4/20)
  • Cash balance at 31 December 2021 amounted to 21.7 MSEK, which will be sufficient to fund the Tourette Study



The Capital Region of Denmark (Region Hovedstaden) was finally able to sign the clinical trial agreements for the two study sites in Copenhagen.

On 16 February 2022, ‘First Patient First Visit’ took place in the phase IIa study in Tourette syndrome, with the first patient randomized on 17 February.


Following the US patent granted to Sepranolone for the treatment of OCD, we have continued to explore possibilities for funding of a clinical study on a potential new combination therapy of Sepranolone, together with SSRIs, for OCD. Tourette is highly co-morbid – 86% of patients have at least one additional disorder, with OCD being particularly prevalent.

To read the Report in full please visit:

For further information, please contact:

Peter Nordkild, CEO

Phone: +45 25 47 16 46


Jakob Dynnes Hansen, CFO

Phone: +45 5132 3698


Certified Adviser

Erik Penser Bank AB

Phone: +46 8-463 83 00



We are a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive compulsive disorder that still lack safe, efficacious pharmaceutical treatments.

The information above was provided by the CEO of Asarina Pharma AB (publ), for publication at 08.00 on February 24, 2022.